- ISIN
- US29337E1029
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 12, 2020
Highlights
- Market Cap
- $3.92B
- Enterprise Value
- $3.78B
- EPS (TTM)
- -$1.63
- Gross Profit (TTM)
- -$46.00K
- EBITDA (TTM)
- -$110.65M
- Year Range
- $14.79 - $55.82
- Target Price
- $43.33
- ROA (TTM)
- -21.25%
- ROE (TTM)
- -21.79%
- Avg. Volume (1M)
- 804K
- Avg. Volume Value (1M)
- $41.86M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ELVN Performance Chart
Enliven Therapeutics Inc. (ELVN) is up 255.9% since the beginning of the year. At $55 per share, ELVN is trading just below its 52-week high of $56. Investors who bought $1,000 worth of ELVN shares 5 years ago would now be looking at an investment worth $2,543.
Loading charts...
Compare this symbol against anything
Returns By Period
Enliven Therapeutics Inc. (ELVN) has returned 255.91% so far this year and 192.63% over the past 12 months.
Enliven Therapeutics Inc.
- 1D
- 1.59%
- 1M
- 10.02%
- 6M
- 107.22%
- YTD
- 255.91%
- 1Y
- 192.63%
- 3Y*
- 42.23%
- 5Y*
- 20.52%
- 10Y*
- —
- ALL TIME*
- -0.34%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ELVN Monthly Returns History
Based on dividend-adjusted daily data since Mar 12, 2020, ELVN's average daily return is +0.14%, while the average monthly return is +2.81%. At this rate, an investment would double in approximately 2.1 years.
Historically, 45% of months were positive and 55% were negative. The best month was Oct 2022 with a return of +94.7%, while the worst month was Jan 2021 at -41.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ELVN closed higher 47% of trading days. The best single day was Sep 7, 2022 with a return of +71.8%, while the worst single day was Jan 6, 2021 at -38.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 71.75% | 12.25% | 32.03% | 5.18% | -4.03% | 28.25% | 8.00% | 255.91% | |||||
| 2025 | -2.84% | -4.71% | -5.52% | -3.76% | -6.18% | 12.89% | -6.23% | 7.76% | 0.99% | 14.41% | -7.77% | -28.70% | -31.56% |
| 2024 | 13.44% | 1.72% | 10.14% | -1.14% | 29.79% | 3.54% | 12.88% | -17.06% | 16.73% | 9.04% | -12.46% | -7.71% | 62.57% |
| 2023 | 12.96% | 16.56% | 1.67% | -13.06% | -3.89% | 11.53% | -7.20% | -17.53% | -12.55% | -9.30% | -9.12% | 22.91% | -15.40% |
| 2022 | -38.22% | 9.35% | 23.68% | -28.72% | -9.70% | 0.83% | -4.10% | 0.85% | 93.22% | 94.74% | -4.05% | -3.99% | 81.78% |
| 2021 | -40.95% | -3.30% | -32.96% | -12.32% | -1.76% | 8.67% | -31.77% | -11.13% | -14.82% | -11.76% | -6.11% | -33.43% | -89.80% |
Benchmark Metrics
Enliven Therapeutics Inc. has an annualized alpha of 25.88%, beta of 0.70, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since March 12, 2020.
- This stock participated in 109.45% of S&P 500 Index downside but only 49.07% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 25.88%
- Beta
- 0.70
- R²
- 0.03
- Upside Capture
- 49.07%
- Downside Capture
- 109.45%
Return for Risk
Risk / Return Rank
ELVN ranks 95 for risk / return — above 95% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Enliven Therapeutics Inc. (ELVN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ELVN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.99 | ||
| Sortino ratioReturn per unit of downside risk | +1.54 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.25 | +0.16 |
| Calmar ratioReturn relative to maximum drawdown | 5.23 | 2.00 | +3.23 |
| Martin ratioReturn relative to average drawdown | 15.54 | 8.49 | +7.04 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Enliven Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Enliven Therapeutics Inc. was 98.20%, occurring on Apr 12, 2022. The portfolio has not yet recovered.
The current Enliven Therapeutics Inc. drawdown is 75.03%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.20%Apr 2022 | 1y 10mo | — | 6y 1moJun 2020 - now | Bear market2022 |
-16.67%May 2020 | 1d | 4d | 5dMay 2020 - May 2020 | — |
-12.88%May 2020 | 1d | 1d | 2dMay 2020 - May 2020 | — |
-9.82%Jun 2020 | 1d | 4d | 4dJun 2020 - Jun 2020 | — |
-8.61%Jun 2020 | 1d | 1d | 1dJun 2020 - Jun 2020 | — |
Drawdown Indicators
| ELVN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.20% | -56.78% | -41.42% |
Max Drawdown (1Y)Largest decline over 1 year | -36.84% | -9.10% | -27.74% |
Max Drawdown (3Y)Largest decline over 3 years | -49.54% | -18.90% | -30.64% |
Max Drawdown (5Y)Largest decline over 5 years | -83.22% | -25.43% | -57.79% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -75.03% | -1.58% | -73.45% |
Average DrawdownAverage peak-to-trough decline | -84.02% | -10.70% | -73.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.37% | 2.14% | +10.23% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Enliven Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Enliven Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ELVN in comparison with other companies in the Biotechnology industry. Currently, ELVN has a P/B value of 7.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ELVN
Add Enliven Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ELVN